Associations between severity of motor function and nonmotor symptoms in Parkinson's disease: A post hoc analysis of the RECOVER study

European Neurology

Volumn 71, Issue 3-4, 2014, Pages 140-147

  Swick, Todd J ^a,f   Friedman, Joseph H ^b   Chaudhuri, K Ray ^c   Surmann, Erwin ^d   Boroojerdi, Babak ^d   Moran, Kimberly ^d   Ghys, Liesbet ^d   Trenkwalder, Claudia ^e  

^a UNIVERSITY OF TEXAS   (United States)

^b BROWN UNIVERSITY   (United States)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d UCB PHARMA   (Belgium)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f Neurology and Sleep Medicine Consultants   (United States)

Author keywords

Motor function; Non Motor Symptom Scale; Nonmotor symptoms; Parkinson's Disease Sleep Scale 2; Sleep; Unified Parkinson's Disease Rating Scale

Indexed keywords

ROTIGOTINE; PLACEBO;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; NONMOTOR SYMPTOM; NONMOTOR SYMPTOM SCALE; PARKINSON DISEASE; PARKINSON DISEASE SLEEP SCALE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SLEEP DISORDER; UNIFIED PARKINSON DISEASE RATING SCALE; VERY ELDERLY; YOUNG ADULT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; MAINTENANCE DRUG DOSE; MODIFIED PARKINSON DISEASE SLEEP SCALE; MOTOR CONTROL; MOTOR DYSFUNCTION; MULTICENTER STUDY; NEUROLOGIC DISEASE ASSESSMENT; NIGHT SLEEP; NON MOTOR SYMPTOM SCALE; OPTIMAL DRUG DOSE; RANDOMIZED CONTROLLED TRIAL; SLEEP QUALITY;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SLEEP DISORDERS; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 84892745245     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000355019     Document Type: Article

References (39)

1. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD: The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Move Disord 2009; 24: 1641-1649.
2. Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR: Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Move Disord 2007; 22: 1623-1629.
3. Shulman LM, Taback RL, Bean J, Weiner WJ: Comorbidity of the nonmotor symptoms of Parkinson's disease. Move Disord 2001; 16: 507-510.
4. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ: Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002; 8: 193-197.
5. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR: The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Move Disord 2011; 26: 399-406.
6. Chaudhuri KR, Healy DG, Schapira AH: Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-245.
7. Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, Miyasaki J, Iverson DJ, Weiner WJ: Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74: 924-931.
8. Global Parkinson's Disease Survey Steering Committee: Factors impacting on quality of life in Parkinson's disease: results from an international survey. Move Disord 2002; 17: 60-67.
9. Aarsland D, Larsen JP, Tandberg E, Laake K: Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48: 938-942.
10. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Chérif AA: Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408-413.
11. Schrag A, Jahanshahi M, Quinn N: What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69: 308-312.
12. Findley L, Aujla M, Bain PG, Baker M, Beech C, Bowman C, Holmes J, Kingdom WK, Mac- Mahon DG, Peto V, Playfer JR: Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Move Disord 2003; 18: 1139-1145.
13. Ahlskog JE: Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Move Disord 2005; 20: 271-282.
14. Benarroch EE: Central neurotransmitters and neuromodulators in cardiovascular regulation; in Mathias CJ, Bannister R (eds): Autonomic Failure, ed 4. Oxford, Oxford University Press, 1999, pp 37-44.
15. Arnulf I, Ferraye M, Fraix V, Benabid AL, Chabardes S, Goetz L, Pollak P, Debû B: Sleep induced by stimulation in the human pedunculopontine nucleus area. Ann Neurol 2010; 67: 546-549.
16. Swick TJ: Parkinson's disease and sleep/wake disturbances. Parkinsons Dis 2012; 2012: 205471.
17. Chaudhuri KR, Schapira AH: Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-474.
18. Chaudhuri KR: The dopaminergic basis of sleep dysfunction and nonmotor symptoms of Parkinson's disease: evidence from functional imaging. Exp Neurol 2009; 216: 247-248.
19. Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W: Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012; 34: 966-978.
20. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH: Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Move Disord 2007; 22: 2398-2404.
21. Jankovic J, Watts RL, Martin W, Boroojerdi B: Transdermal rotigotine: double-blind, placebo- controlled trial in Parkinson disease. Arch Neurol 2007; 64: 676-682.
22. LeWitt PA, Lyons KE, Pahwa R: Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007; 68: 1262-1267.
23. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B: Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double- blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513-520.
24. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J: Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68: 272-276.
25. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR: Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a doubleblind, randomized, placebo-controlled study (RECOVER). Move Disord 2011; 26: 90-99.
26. Martínez-Martín P, Gil-Nagel A, Gracia LM, Gómez JB, Martínez-Sarriés J, Bermejo F, Cooperative Multicentric Group: Unified Parkinson's Disease Rating Scale characteristics and structure. Move Disord 1994; 9: 76-83.
27. Martinez-Martin P, Rodriguez-Blazquez C, Abe K, Bhattacharyya KB, Bloem BR, Carod- Artal FJ, Prakash R, Esselink RA, Falup-Pecurariu C, Gallardo M, Mir P, Naidu Y, Nicoletti A, Sethi K, Tsuboi Y, van Hilten JJ, Visser M, Zappia M, Chaudhuri KR: International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 2009; 73: 1584-1591.
28. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH: The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Move Disord 2007; 22: 1901-1911.
29. Trenkwalder C, Kohnen R, Högl B, Metta V, Sixel-Döring F, Frauscher B, Hülsmann J, Martinez-Martin P, Chaudhuri KR: Parkinson's disease sleep scale-validation of the revised version PDSS-2. Move Disord 2011; 26: 644-652.
30. Storch A, Schneider CB, Wolz M, Sturwald Y, Nebe A, Odin P, Mahler A, Fuchs G, Jost WH, Chaudhuri KR, Koch R, Reichmann H, Ebersbach G: Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013; 80: 800-809.
31. Antonini A, Albin RL: Dopaminergic treatment and nonmotor features of Parkinson disease: the horse lives. Neurology 2013; 80: 784-785.
32. Antonini A, Barone P, Marconi R, Morgante L, Zappulla S, Pontieri FE, Ramat S, Ceravolo MG, Meco G, Cicarelli G, Pederzoli M, Manfredi M, Ceravolo R, Mucchiut M, Volpe G, Abbruzzese G, Bottacchi E, Bartolomei L, Ciacci G, Cannas A, Randisi MG, Petrone A, Baratti M, Toni V, Cossu G, Del Dotto P, Bentivoglio AR, Abrignani M, Scala R, Pennisi F, Quatrale R, Gaglio RM, Nicoletti A, Perini M, Avarello T, Pisani A, Scaglioni A, Martinelli PE, Iemolo F, Ferigo L, Simone P, Soliveri P, Troianiello B, Consoli D, Mauro A, Lopiano L, Nastasi G, Colosimo C: The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J Neurol 2012; 259: 2621-2631.
33. van Rooden SM, Visser M, Verbaan D, Marinus J, van Hilten JJ: Patterns of motor and non-motor features in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009; 80: 846-850.
34. Tandberg E, Larsen JP, Karlsen K: A community- based study of sleep disorders in patients with Parkinson's disease. Move Disord 1998; 13: 895-899.
35. Partinen M: Sleep disorder related to Parkinson's disease. J Neurol 1997; 244:S3-S6.
36. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL: Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982; 5: 183-194.
37. van Hilten JJ, Weggeman M, van der Velde EA, Kerkhof GA, van Dijk JG, Roos RA: Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Trans 1993; 5: 235-244.
38. Lees AJ, Blackburn NA, Campbell VL: The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988; 11: 512-519.
39. Friedman JH, Chou KL: Sleep and fatigue in Parkinson's disease. Parkinsonism Relat Disord 2004; 10:S27-S35.